Immuron Reports Positive Results in NASH Clinical Trial
March 07, 2018 18:30 ET
|
Immuron Limited
Headlines: First-In Class Anti-LPS Mechanism of Action confirmed for IMM-124EResults demonstrate excellent safety and tolerabilityStatistically significant reduction in serum endotoxin/...